|
Jan 8
|
Merck to acquire Harpoon Therapeutics in $680M deal
|
|
Jan 8
|
Merck (MRK) Begins Pivotal Studies on Four Cancer Candidates
|
|
Jan 8
|
Merck Is in Advanced Talks to Buy Cancer Drugmaker Harpoon Therapeutics
|
|
Jan 8
|
The Zacks Analyst Blog Highlights Merck, Salesforce, Philip Morris International, Novartis and CME Group
|
|
Jan 8
|
Merck Stock Has Been A Laggard For Seven Months. Is It Staging A Comeback?
|
|
Jan 8
|
Merck to Buy Harpoon Therapeutics for $680 Million
|
|
Jan 8
|
Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline
|
|
Jan 8
|
Boeing, Alaska Air, Spirit AeroSystems fall premarket; Nvidia, Moderna rise
|
|
Jan 5
|
Top Analyst Reports for Merck, Salesforce & Philip Morris
|
|
Jan 5
|
Healthcare Champions Kick Off 2024
|
|
Jan 5
|
Merck Announces Phase 3 Trial Initiations for Four Investigational Candidates From its Promising Hematology and Oncology Pipeline
|
|
Jan 5
|
Merck (NYSE:MRK) Has A Pretty Healthy Balance Sheet
|
|
Jan 4
|
UPDATE 1-Merck seeks GLP-1 drugs with benefits beyond weight loss - CEO
|
|
Jan 4
|
Merck seeks GLP-1 drugs with benefits beyond weight loss - CEO
|
|
Jan 4
|
5 FDA decisions to watch in the first quarter
|
|
Jan 3
|
Pharma Stocks Are on a Health Kick
|
|
Jan 3
|
Company News for Jan 3, 2024
|
|
Jan 3
|
Merck to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
|
|
Dec 22
|
12 Best Undervalued Stocks to Buy According to Reddit
|
|
Dec 22
|
Patritumab Deruxtecan Granted Priority Review in the U.S. for Certain Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
|